{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:44:47Z","timestamp":1773672287222,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00329-8","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:57:55Z","timestamp":1761987475000},"page":"237-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Malaysia: Epidemiological Data Update"],"prefix":"10.1007","volume":"12","author":[{"given":"Karan","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe H.","family":"Kyaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharlini","family":"Surendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iustina","family":"Chirila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Fernando","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masliyana","family":"Husin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Seah Keng","family":"Tok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek Jason","family":"Jayaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheamini","family":"Sivasampu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josie","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Yarnoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"329_CR1","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023 [updated 2023; cited May 4, 2023]; Available from: https:\/\/covid19.who.int\/table."},{"issue":"1","key":"329_CR2","doi-asserted-by":"publisher","first-page":"e0296488","DOI":"10.1371\/journal.pone.0296488","volume":"19","author":"PSK Tok","year":"2024","unstructured":"Tok PSK, Kang KY, Ng SW, Ab Rahman N, Syahmi MA, Pathmanathan MD, et al. Post COVID-19 condition among adults in Malaysia following the Omicron wave: a prospective cohort study. PLoS ONE. 2024;19(1):e0296488.","journal-title":"PLoS ONE"},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijid.2022.10.044","volume":"125","author":"NAM Azami","year":"2022","unstructured":"Azami NAM, Perera D, Thayan R, AbuBakar S, Sam IC, Salleh MZ, et al. SARS-CoV-2 genomic surveillance in Malaysia: displacement of B.1.617.2 with AY lineages as the dominant Delta variants and the introduction of Omicron during the fourth epidemic wave. Int J Infect Dis. 2022;125:216\u201326.","journal-title":"Int J Infect Dis"},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"1289622","DOI":"10.3389\/fpubh.2024.1289622","volume":"12","author":"MN Md Nadzri","year":"2024","unstructured":"Md Nadzri MN, Md Zamri ASS, Singh S, Sumarni MG, Lai CH, Tan CV, et al. Description of the COVID-19 epidemiology in Malaysia. Front Public Health. 2024;12:1289622.","journal-title":"Front Public Health"},{"issue":"8","key":"329_CR5","first-page":"1644","volume":"13","author":"TY Lee","year":"2023","unstructured":"Lee TY, Lim WF, Ang GY, Yu CY. Genomic surveillance of SARS-CoV-2 in Malaysia during the era of endemic COVID-19. Life (Basel). 2023;13(8):1644.","journal-title":"Life (Basel)"},{"issue":"1","key":"329_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41467-023-36566-1","volume":"14","author":"R Grewal","year":"2023","unstructured":"Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. Nat Commun. 2023;14(1):1273.","journal-title":"Nat Commun"},{"issue":"14","key":"329_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMc2210093","volume":"387","author":"S Collie","year":"2022","unstructured":"Collie S, Nayager J, Bamford L, Bekker L-G, Zylstra M, Gray G. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. N Engl J Med. 2022;387(14):1332\u20133.","journal-title":"N Engl J Med"},{"key":"329_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.31.22279444","author":"F Kirsebom","year":"2022","unstructured":"Kirsebom F, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Effectiveness of the COVID-19 vaccines against severe disease with Omicron sub-lineages BA. 4 and BA. 5 in England. MedRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.08.31.22279444.","journal-title":"MedRxiv"},{"key":"329_CR9","unstructured":"The Star. Covid-19: MOH targets to have 50% of children vaccinated before start of school session, says KJ. 2022 [updated 2022 13 March 2022; cited 2 June 2022]; Available from: https:\/\/www.thestar.com.my\/news\/nation\/2022\/03\/13\/covid-19-moh-targets-to-have-50-of-children-vaccinated-before-start-of-school-session-says-kj."},{"issue":"1","key":"329_CR10","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1038\/s41598-024-59195-0","volume":"14","author":"CMJ Khoo","year":"2024","unstructured":"Khoo CMJ, Dea EZQ, Law LY, Wong SST, Ng KY, Bakhtiar A. Acceptability of COVID-19 booster vaccine in Malaysia: a cross-sectional study. Sci Rep. 2024;14(1):8421.","journal-title":"Sci Rep"},{"issue":"1","key":"329_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14760584.2023.2245465","volume":"22","author":"K Thakkar","year":"2023","unstructured":"Thakkar K, Spinardi J, Kyaw MH, Yang J, Mendoza CF, Dass M, et al. Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia. Expert Rev Vaccines. 2023;22(1):714\u201325.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"329_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/13696998.2022.2071427","volume":"25","author":"M Di Fusco","year":"2022","unstructured":"Di Fusco M, Marczell K, Deger KA, Moran MM, Wiemken TL, Cane A, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605\u201317.","journal-title":"J Med Econ"},{"issue":"5","key":"329_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making. 2012;32(5):733\u201343.","journal-title":"Med Decis Making"},{"key":"329_CR14","unstructured":"Department of Statistics Malaysia. Mid-year population estimates by age group, ethnic group and sex, Malaysia, 2024. [cited]; Available from: http:\/\/dosm.gov.my."},{"issue":"8","key":"329_CR15","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1016\/S2214-109X(20)30264-3","volume":"8","author":"A Clark","year":"2020","unstructured":"Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003\u201317.","journal-title":"Lancet Glob Health"},{"key":"329_CR16","unstructured":"Ministry of Health Malaysia. COVIDNOW in Malaysia. 2023 [updated 2023 20 Jan 2025; cited]; Available from: https:\/\/covidnow.moh.gov.my\/."},{"key":"329_CR17","doi-asserted-by":"crossref","unstructured":"Mustapha M, Togo K, Volkman H, Yang J, Yehoshua A, Di Fusco M, et al. Under-Reporting of SARS-CoV-2 Infections in 27 Countries, 2020\u20132022. 2024. Available at SSRN 5014145.","DOI":"10.2139\/ssrn.5014145"},{"issue":"12","key":"329_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","volume":"22","author":"SY Tartof","year":"2022","unstructured":"Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5. Lancet Infect Dis. 2022;22(12):1663\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"329_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2213-2600(22)00101-1","volume":"10","author":"SY Tartof","year":"2022","unstructured":"Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case\u2013control study. Lancet Respir Med. 2022;10(7):689\u201399.","journal-title":"Lancet Respir Med"},{"key":"329_CR20","doi-asserted-by":"crossref","unstructured":"Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Yaron S, et al. Effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes: An observational cohort study. 2023. Available at SSRN 4314067.","DOI":"10.2139\/ssrn.4314067"},{"key":"329_CR21","doi-asserted-by":"crossref","unstructured":"Link-Gelles R. Early Estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA. 5\u2013and XBB\/XBB. 1.5\u2013related sublineages among immunocompetent adults\u2014Increasing Community Access to Testing Program, United States, December 2022\u2013January 2023. MMWR Morbidity and Mortality Weekly Report. 2023; 72.","DOI":"10.15585\/mmwr.mm7205e1"},{"issue":"42","key":"329_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.15585\/mmwr.mm7142a3","volume":"71","author":"D Surie","year":"2022","unstructured":"Surie D, Bonnell L, Adams K, Gaglani M, Ginde AA, Douin DJ, et al. Effectiveness of monovalent mRNA vaccines against COVID-19\u2013associated hospitalization among immunocompetent adults during BA. 1\/BA. 2 and BA. 4\/BA. 5 predominant periods of SARS-CoV-2 Omicron variant in the United States\u2014IVY network, 18 states, December 26, 2021\u2013August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327\u201334.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"329_CR23","unstructured":"Surie D. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19\u2013Associated Hospitalization Among Immunocompetent Adults Aged\u2265 65 Years\u2014IVY Network, 18 States, September 8\u2013November 30, 2022. MMWR Morbidity and mortality weekly report. 2022; 71."},{"issue":"10","key":"329_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.47102\/annals-acadmedsg.V52N10p522","volume":"52","author":"J Li","year":"2023","unstructured":"Li J, Nadua K, Chong CY, Yung CF. Long COVID prevalence, risk factors and impact of vaccination in the paediatric population: a survey study in Singapore. Ann Acad Med Singap. 2023;52(10):522\u201332.","journal-title":"Ann Acad Med Singap"},{"key":"329_CR25","unstructured":"Department of Statistics Malaysia. Consumer Price Index Report: Aug 2024. 2024 [updated 2024 August 2024; cited 06\/02\/2025]; Available from: https:\/\/open.dosm.gov.my\/publications\/cpi_2024-08."},{"key":"329_CR26","unstructured":"World Bank Group. Government expenditure per student, secondary (% of GDP per capita)\u2014Malaysia. 2020 [updated 2020; cited 2025 March 4]; Available from: https:\/\/data.worldbank.org\/indicator\/SE.XPD.SECO.PC.ZS?locations=MY."},{"issue":"4","key":"329_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539\u201345.","journal-title":"Value Health"},{"issue":"3","key":"329_CR28","doi-asserted-by":"publisher","first-page":"e17030","DOI":"10.1371\/journal.pone.0017030","volume":"6","author":"AJ van Hoek","year":"2011","unstructured":"van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS ONE. 2011;6(3):e17030.","journal-title":"PLoS ONE"},{"issue":"4","key":"329_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0002-9343(02)01222-6","volume":"113","author":"KJ Smith","year":"2002","unstructured":"Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113(4):300\u20137.","journal-title":"Am J Med"},{"issue":"1","key":"329_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-019-1081-5","volume":"17","author":"F Barbut","year":"2019","unstructured":"Barbut F, Galperine T, Vanhems P, Le Monnier A, Durand-Gasselin B, Canis F, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6.","journal-title":"Health Qual Life Outcomes"},{"key":"329_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","volume":"5","author":"D Sharma","year":"2021","unstructured":"Sharma D, Aggarwal AK, Downey LE, Prinja S. National healthcare economic evaluation guidelines: a cross-country comparison. PharmacoEconomics-Open. 2021;5:349\u201364.","journal-title":"PharmacoEconomics-Open"},{"key":"329_CR32","unstructured":"Ministry of Finance Malaysia. Press Citations: Budget 2023: Public health services capacity strengthened, RM36.1 bln allocated to MOH. 2022 [updated 2022; cited 24\/04\/2025]; Available from: https:\/\/www.mof.gov.my\/portal\/en\/news\/press-citations\/budget-2023-public-health-services-capacity-strengthened-rm36-1-bln-allocated-to-moh."},{"issue":"2","key":"329_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/biology11020190","volume":"11","author":"Z Xu","year":"2022","unstructured":"Xu Z, Zhang H, Huang Z. A continuous Markov-chain model for the simulation of COVID-19 epidemic dynamics. Biology. 2022;11(2):190.","journal-title":"Biology"},{"issue":"6","key":"329_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/rsp3.12372","volume":"12","author":"Z Dehghan Shabani","year":"2020","unstructured":"Dehghan Shabani Z, Shahnazi R. Spatial distribution dynamics and prediction of COVID-19 in Asian countries: Spatial Markov chain approach. Reg Sci Policy Pract. 2020;12(6):1005\u201325.","journal-title":"Reg Sci Policy Pract"},{"issue":"10","key":"329_CR35","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.cmi.2021.07.002","volume":"27","author":"A Lochen","year":"2021","unstructured":"Lochen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infec. 2021;27(10):1546\u201357.","journal-title":"Clin Microbiol Infec"},{"key":"329_CR36","doi-asserted-by":"publisher","first-page":"110057","DOI":"10.1016\/j.chaos.2020.110057","volume":"139","author":"I Cooper","year":"2020","unstructured":"Cooper I, Mondal A, Antonopoulos CG. A SIR model assumption for the spread of COVID-19 in different communities. Chaos Solitons Fractals. 2020;139:110057.","journal-title":"Chaos Solitons Fractals"},{"key":"329_CR37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.apm.2020.10.019","volume":"90","author":"JE Amaro","year":"2021","unstructured":"Amaro JE, Dudouet J, Orce JN. Global analysis of the COVID-19 pandemic using simple epidemiological models. Appl Math Model. 2021;90:995\u20131008.","journal-title":"Appl Math Model"},{"key":"329_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.arcontrol.2020.10.005","volume":"50","author":"GC Calafiore","year":"2020","unstructured":"Calafiore GC, Novara C, Possieri C. A time-varying SIRD model for the COVID-19 contagion in Italy. Annu Rev Control. 2020;50:361\u201372.","journal-title":"Annu Rev Control"},{"key":"329_CR39","doi-asserted-by":"publisher","first-page":"109846","DOI":"10.1016\/j.chaos.2020.109846","volume":"135","author":"F Nda\u00efrou","year":"2020","unstructured":"Nda\u00efrou F, Area I, Nieto JJ, Torres DF. Mathematical modeling of COVID-19 transmission dynamics with a case study of Wuhan. Chaos Solitons Fractals. 2020;135:109846.","journal-title":"Chaos Solitons Fractals"},{"issue":"11","key":"329_CR40","doi-asserted-by":"publisher","first-page":"e2240332","DOI":"10.1001\/jamanetworkopen.2022.40332","volume":"5","author":"AM O\u2019Hare","year":"2022","unstructured":"O\u2019Hare AM, Vig EK, Iwashyna TJ, Fox A, Taylor JS, Viglianti EM, et al. Complexity and challenges of the clinical diagnosis and management of long COVID. JAMA Netw Open. 2022;5(11):e2240332.","journal-title":"JAMA Netw Open"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00329-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:31:25Z","timestamp":1773667885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00329-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00329-8","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karan Thakkar, Moe H. Kyaw, Sharlini Surendran, Iustina Chirila, and Carlos Fernando Mendoza, are employees of Pfizer and may hold stock or stock options of Pfizer. Josie Dodd and Ben Yarnoff are employees of PPD Evidera Health Economics and Market Access, Thermo Fisher Scientific, which received financial support from Pfizer in connection with the study and the development of this manuscript. Masliyana Husin, Peter Seah Keng Tok, Vivek Jason Jayaraj, and Sheamini Sivasampu have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}